## Founding Date | 2004 |

## Total Funding | $355 m |

## Investors | Sevin Rosen Funds, TPG, Redmile Group, Delphi Ventures, Ventures West, WRF Capital, H.I.G. Capital, Novo Ventures |

In total, Alder BioPharmaceuticals had raised $355 m. Alder BioPharmaceuticals is a subsidiary of Lundbeck

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|

## Revenue | |||||

## Cost of goods sold | 113.0k | ||||

## R&D expense | 33.4m | 69.6m | 132.8m | 252.9m | 239.1m |

## General and administrative expense | 12.5m | 16.7m | 26.1m | 38.1m | 47.5m |

## Operating expense total | 45.9m | 86.3m | 158.9m | 291.0m | 286.6m |

## EBIT | 8.8m | (86.3m) | (157.9m) | (291.0m) | (286.6m) |

## Interest expense | 104.0k | 859.0k | 1.8m | 2.8m | 9.6m |

## Interest income | 44.0k | 702.0k | 2.0m | 2.5m | 8.9m |

## Investment income | (185.0k) | (643.0k) | (222.0k) | ||

## Pre tax profit | 8.9m | (85.5m) | (156.1m) | (288.2m) | (296.2m) |

## Net Income | 8.9m | (85.5m) | (156.3m) | (288.9m) | (296.4m) |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|

## Cash | 46.8m | 206.5m | 116.2m | 76.9m | 87.9m |

## Accounts Receivable | 113.0k | 113.0k | |||

## Prepaid Expenses | 11.0m | 7.4m | |||

## Inventories | 28.2m | 936.0k | |||

## Current Assets | 60.7m | 322.2m | 393.2m | 287.3m | 419.8m |

## PP&E | 1.2m | 2.0m | 7.1m | 5.6m | 6.4m |

## Total Assets | 64.4m | 400.0m | 409.2m | 303.1m | 426.2m |

## Accounts Payable | 1.9m | 4.7m | 10.4m | 7.5m | 8.9m |

## Current Liabilities | 5.0m | 12.4m | 25.9m | 23.4m | 28.2m |

## Long-term debt | 182.1m | ||||

## Total Debt | 182.1m | ||||

## Total Liabilities | 26.4m | 23.9m | 212.5m | ||

## Common Stock | 7.0k | 7.0k | |||

## Additional Paid-in Capital | 196.1m | 610.4m | 761.5m | 946.9m | 1.1b |

## Retained Earnings | (136.9m) | (222.4m) | (378.6m) | (667.5m) | (963.9m) |

## Total Equity | 387.5m | 382.8m | 279.3m | 110.0m | |

## Financial Leverage | 1 x | 1.1 x | 1.1 x | 3.9 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|

## Net Income | 8.9m | (85.5m) | (156.3m) | (288.9m) | (296.4m) |

## Depreciation and Amortization | 701.0k | 751.0k | 1.7m | 3.0m | 2.6m |

## Accounts Receivable | 203.0k | 113.0k | 113.0k | ||

## Inventories | 95.0k | (936.0k) | 936.0k | ||

## Accounts Payable | (312.0k) | 2.8m | 5.5m | (2.4m) | 1.3m |

## Cash From Operating Activities | (47.7m) | (81.2m) | (159.7m) | (226.6m) | (250.8m) |

## Purchases of PP&E | (649.0k) | (1.2m) | (6.6m) | (2.0m) | (3.1m) |

## Cash From Investing Activities | (9.7m) | (167.3m) | (67.7m) | 34.4m | (121.1m) |

## Cash From Financing Activities | 81.0m | 408.2m | 137.1m | 162.9m | 377.9m |

## Net Change in Cash | (29.3m) | 6.0m | |||

## Interest Paid | 3.6m |

USD | Q1, 2014 |
---|---|

## Financial Leverage | -0.1 x |